SCHEMBL7181283

SCHEMBL7181283

CCOc1cccc(OCC)c1C(=O)P(=O)(C(=O)c1c(C)cc(C)c(C)c1C)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
GLA P06280 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 1/20 0.37
HCRTR1 O43613 1/20 0.36
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36
KCNK3 O14649 2/20 0.36
KCNK9 Q9NPC2 2/20 0.36
RAB9A P51151 1/20 0.36
EZH2 Q15910 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175426 0.88 GLA (0.41) L3MBTL1GLAMRGPRX4MEN1KMT2A
SCHEMBL7181658 0.86 CA12 (0.43) L3MBTL1KMT2APOLBALDH1A1TSHR
SCHEMBL7189008 0.86 L3MBTL1 (0.44) L3MBTL1GLAMRGPRX4MEN1KMT2A
SCHEMBL7183691 0.85 RXFP1 (0.42) L3MBTL1GLAMRGPRX4MEN1KMT2A
SCHEMBL7181616 0.84 KMT2A (0.36) MEN1KMT2APOLBALDH1A1RAB9A
SCHEMBL7182648 0.83 MEN1 (0.33) L3MBTL1MEN1KMT2APOLBALDH1A1
SCHEMBL7182338 0.82 SMN1; SMN2 (0.51) L3MBTL1GLAMEN1KMT2APOLB
SCHEMBL7177289 0.82 L3MBTL1 (0.34) L3MBTL1MEN1KMT2APOLBALDH1A1
SCHEMBL7180464 0.82 KMT2A (0.34) MEN1KMT2APOLBALDH1A1RAB9A
SCHEMBL7174855 0.82 GFER (0.35) MEN1KMT2APOLBALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 L3MBTL1 302/4885GLA 4603/4885MRGPRX4 3913/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 L3MBTL1 126/4885GLA 4675/4885MRGPRX4 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.